Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats

Fundamental and Applied Toxicology

Volumn 32, Issue 1, 1996, Pages 53-65

  Graziano, Michael J ^a   Courtney, Cynthia L ^a   Meierhenry, Earl F ^a,b   Kheoh, Thian ^a   Pegg, David G ^a   Gough, Alex W ^a  

^a PFIZER INC   (United States)

^b CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; INTESTINE CANCER; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; SKIN CANCER;

EID: 85033062532     PISSN: 02720590     EISSN: None     Source Type: Journal    
DOI: 10.1006/faat.1996.0106     Document Type: Article

References (63)

1. Ames, B. N., and Gold, L. S. (1990). Chemical carcinogenesis: Too many rodent carcinogens. Proc. Natl. Acad. Sci. USA 87, 7772-7776.
2. Andersson, H. C., and Kihlman, B. A. (1989). The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II. I. m-Amsa. Carcinogenesis 10, 123-130.
3. Arlin, Z. A. (1989). A special role for amsacrine in the treatment of acute leukemia. Cancer Invest. 7, 607-609.
4. Arlin, Z. A., Feldman, E., Kempin, S., Ahmed, T., Mittelman, A., Savona, S., Ascensao, J., Baskind, P., Sullivan, P., Fuhr, H. G., and Mertelsmann, R. (1988). Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood 72, 433-435.
5. Arlin, Z. A., Feldman, E. J., Mittelman, A., Ahmed, T., Puccio, C., Chun, H. G., Cook, P., Baskind, P., Marboe, C., and Mehta, R. (1991). Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer 68, 1198-1200.
6. Arlin, Z. A., Sklaroff, R. B., Gee, T. S., Kempin, S. J., Howard, J., Clarkson, B. D., and Young, C. W. (1980). Phase I and II trial of 4′-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia. Cancer Res. 40, 3304-3306.
7. Armitage, P. (1974a). Statistical Methods in Medical Research, pp. 135-138. Wiley, New York.
8. Armitage, P. (1974b). Statistical Methods in Medical Research, pp. 363-365. Wiley, New York.
9. Ashby, J., and Tennant, R. W. (1988). Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/ NTP. Mutat. Res. 204, 17-115.
10. Backer, L. C., Allen, J. W., Harrington-Brock, K., Campbell, J. A., DeMarini, D. M., Doerr, C. L., Howard, D. R., Kligerman, A. D., and Moore, M. M. (1990). Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro. Mutagenesis 5, 541-547.
11. Bombard, E., and Rinke, M. (1994). Frequency of spontaneous tumours in Wistar rats in 2-year studies. Exp. Toxicol. Pathol. 46, 17-29.
12. Carr, C. J., and Kolbye, A. C. (1991). A critique of the use of the maximum tolerated dose in bioassays to assess cancer risks from chemicals. Regul. Toxicol. Pharmacol. 14, 78-87.
13. Clayson, D. B., Iverson, F., and Mueller, R. (1991). An appreciation of the maximum tolerated dose: An inadequately precise decision point in designing a carcinogenesis bioassay? Teratogen. Carcinog. Mutagen. 11, 279-296.
14. Courtney, C. L., Hawkins, K. L., and Graziano, M. J. (1992a). Granular basal cell tumor in a Wistar rat. Toxicol. Pathol. 20, 122-124.
15. Courtney, C. L., Hawkins, K. L., Meierhenry, E. F., and Graziano, M. J. (1992b). Immunohistochemical and ultrastructural characterization of granular cell tumors of the female reproductive tract in two aged Wistar rats. Vet. Pathol. 29, 86-89.
16. Covey, J. M., Kohn, K. W., Kerrigan, D., Tilchen, E. J., and Pommier, Y. (1988). Topoisomerase II-mediated DNA damage produced by 4′-(9-acridinylamino)-methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: Relation to cytotoxicity. Cancer Res. 48, 860-865.
17. Cummings, J., and Smyth, J. F. (1993). DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann. Oncol. 4, 533-543.
18. Cysyk, R. L., Shoemaker, D., and Adamson, R. H. (1977). The pharmacologic disposition of 4′-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats. Drug Metab. Disp. 5, 579-590.
19. Dekker, A. W., Nieuwenhuis, H. K., and Verdonck, L. F. (1990). Intermediate-dose cytosine arabinoside and amsacrine. Cancer 65, 1891-1894.
20. DeMarini, D. M., Doerr, C. L., Meyer, M. K., Brock, K. H., Hozier, J., and Moore, R. M. (1987). Mutagenicity of m-AMSA and o-AMSA in mammalian cells due to clastogenic mechanism: Possible role of topoisomerase. Mutagenesis 2, 349-355.
21. Ferguson, L. R., and Denny, W. A. (1991). The genetic toxicology of acridines. Mutat. Res. 258, 123-160.
22. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., and Skipper, H. E. (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219-244.
23. Freund, M., Giller, S., Hinrichs, F., Baars, A., Meran, J., Korfer, A., Link, H., and Poliwoda, H. (1991). Five-day 4′-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia. J. Cancer Res. Clin. Oncol. 117, 489-492.
24. Gallo, F., Morale, M. C., Sambataro, D., Farinella, Z., Scapagnini, U., and Marchetti, B. (1993). The immune system response during development and progression of carcinogen-induced rat mammary tumors: Prevention of tumor growth and restoration of immune system responsiveness by thymopentin. Breast Cancer Res. Treat. 27, 221-237.
25. Gart, J. J., Chu, K. C., and Tarone, R. E. (1979). Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. J. Natl. Cancer Inst. 62, 957-974.
26. Gold, L. S., Slone, T. H., Stern, B. R., and Bernstein, L. (1993). Comparison of target organs of carcinogenicity for mutagenic and non-mutagenic chemicals. Mutat. Res. 286, 75-100.
27. Gough, A., Courtney, C., and Graziano, M. (1994). Induction of small intestinal adenocarcinomas in Wistar rats administered amsacrine. Exp. Toxicol. Pathol. 46, 275-281.
28. Haseman, J. K., and Lockhart, A.-M. (1993). Correlations between chemically related site-specific carcinogenic effects in long-term studies in rats and mice. Environ. Health Perspect. 101, 50-54.
29. Henry, M. C., Port, C. D., and Levine, B. S. (1980). Preclinical toxicologic evaluation of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in mice, dogs, and monkeys. Cancer Treat. Rep. 64, 855-860.
30. Hines, J. D., Oken, M. M., Mazza, J. J., Keller, A. M., Streeter, R. R., and Glick, J. H. (1984). High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J. Clin. Oncol. 2, 545-549.
31. Holmstrom, M., and Winters, V. (1992). Micronucleus induction by camptothecin and amsacrine in bone marrow of male and female CD-1 mice. Mutagenesis 7, 189-193.
32. Iwamoto, Y., Ferguson, L. R., Pogai, H. B., Uzuhashi, T., Kurita, A., Yangihara, Y., and Denny, W. A. (1992). Mutagenic activities of azido analogues of amsacrine and other 9-anilinoacridines in Salmonella typhimurium and their enhancement by photoirradiation. Mutat. Res. 280, 233-244.
33. Jehn, U., and Heinemann, V. (1991). New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA. Anticancer Res. 11, 705-712.
34. Kaldor, J. M., Day, N. E., and Hemminki, K. (1988). Quantifying the carcinogenicity of antineoplastic drugs. Eur. J. Cancer Clin. Oncol. 24, 703-711.
35. Kaplan, E. L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
36. Lehr, R. E., Wood, A. W., Levin, W., Conney, A. H., and Jerina, D. M. (1988). Benzacridines and dibenzacridines. Metabolism, mutagenicity and carcinogenicity. In Polycyclic Aromatic Hydrocarbon Carcinogenesis: Structure-Activity Relationships. (S. K. Yang and B. D. Silverman, Eds.), pp. 31-58. CRC Press, Boca Raton.
37. Legha, S. S., Keating, M. J., McCredie, K. B., Bodey, G. P., and Freireich, E. J. (1982). Evaluation of AMSA in previously treated patients with acute leukemia: Results of therapy in 109 adults. Blood 60, 484-490.
38. Lim, M., Liu, M. F., Jacobson-Kram, D., and Williams, J. R. (1986). Induction of sister chromatid exchanges by inhibitors of topoisomerases. Cell Biol. Toxicol. 2, 485-494.
39. Liu, L. F. (1989). DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58, 351-375.
40. Marselos, M., and Vainio, H. (1991). Carcinogenic properties of pharmaceutical agents evaluated in the IARC Monographs programme. Carcinogenesis 12, 1751-1766.
41. Maschmeyer, G., Willborn, K., and Heit, W. (1992). AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment. Leuk. Lymphoma 8, 365-369.
42. Mather, G. G., Talcott, P. A., and Exon, J. H. (1994). Characterization of a chemically induced tumor model and the effects of natural killer cell depletion by antiasialo GM-1. Immunobiology 190, 333-345.
43. Miller, L. P., Pyesmany, A. F., Wolff, L. J., Rogers, P. C., Siegel, S. E., Wells, R. J., Buckley, J. D., and Hammond, G. D. (1991). Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group. Cancer 67, 2235-2240.
44. Minford, J., Pommier, Y., Filipski, J., Kohn, K. W., Kerrigan, D., Mattern, M., Michaels, S., Schwartz, R., and Zwelling, L. A. (1986). Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry 25, 9-16.
45. Monro, A., and Mordenti, J. (1995). Expression of exposure in negative carcinogenicity studies: Dose/body weight, dose/body surface area, or plasma concentrations? Toxicologic Pathol. 23, 187-198.
46. National Cancer Institute (1977). Bioassay of Proflavine for Possible Carcinogenicity. CAS 952-23-8. Carcinogenesis Technical Report Series 5, DHEW Publication (NIH) 77-805.
47. Nelson, E. M., Tewey, K. M., and Liu, L. F. (1984). Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc. Natl. Acad. Sci. USA 81, 1361-1365.
48. Peck, R. M., Tan, T. K., and Peck, E. B. (1976). Pulmonary carcinogenesis by derivatives of polynuclear aromatic alkylating agents. Cancer Res. 36, 2423-2427.
49. Pegg, D. G., Watkins, J. R., Graziano, M. J., and McKenna, M. J. (1996). Subchronic intravenous toxicity of the antineoplastic drug, amsacrine, in male Wistar rats. Fund. Appl. Toxicol. 32, 45-52.
50. Peto, R., Pike, M. C., Day, N. E., Gray, R. G., Lee, P. N., Parish, S., Peto, J., Richards, S., and Wahrendorf, J. (1980). Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In Long-Term and Short-Term Screening assays for Carcinogens: A Critical Appraisal, IARC Monographs Suppl. 2, pp. 311-426. International Agency for Research on Cancer.
51. Pommier, Y., Covey, J., Kerrigan, D., Mattes, W., Markovits, J., and Kohn, K. W. (1987). Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines. Biochem. Pharmacol. 36, 3477-3486.
52. Pommier, Y., Schwartz, R. E., Kohn, K. W., and Zwelling, L. A. (1984). Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents. Biochemistry 23, 3194-3201.
53. Rieche, K. (1984). Carcinogenicity of antineoplastic agents in man. Cancer Treat. Rev. 11, 39-67.
54. Rowe, T. C., Chen, G. L., Hsiang, Y.-H., and Liu, L. F. (1986). DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 46, 2021-2026.
55. Ryffel, B., Mihatsch, M. J., and Fisher, G. L. (1992). Immunosuppression and cancer: The ciclosporin case. Drug Chem. Toxicol. 15, 95-115.
56. Spina, M., and Tirelli, U. (1992). Human immunodeficiency virus as a risk factor in miscellaneous cancers. Curr. Opin. Oncol. 4, 907-910.
57. Spinolo, J. A., Dicke, K. A., Horwitz, L. J., Jagannath, S., Zander, A. R., Auber, M. L., and Spitzer, G. (1990). Double intensification with amsacrine/high dose ara-c and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia. Bone Marrow Transplant 5, 111-118.
58. Tarone, R. E. (1975). Tests for trend in life table analysis. Biometrika 62, 679-682.
59. Tarone, R. E., and Ware, J. (1977). On distribution-free tests for equality of survival distributions. Biometrika 64, 156-160.
60. Walsh, K. M., and Poteracki, J. (1994). Spontaneous neoplasms in control Wistar rats. Fund. Appl. Toxicol. 22, 65-72.
61. Willemze, R., Jager, U., Jehn, U., Stryckmans, P., Bury, J., Suciu, S., Solbu, G., Zittoun, R., Burghouts, J., Lowenberg, B., Abels, J., and Cauchie, CH. (1988). Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: An EORTC Leukemia Cooperative Group phase II study. Eur. J. Cancer Clin. Oncol. 24, 1721-1725.
62. Zittoun, R., Jehn, U., Fiere, D., Haanan, B., Lowenburg, B., Willemze, R., Abels, J., Bury, J., Peetermans, M., Hayat, M., Suciu, S., Solbu, G., and Stryckmans, P. (1989). Alternating v repeated postremission treatment in adult acute myelogenous leukemia: A randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 73, 896-906.
63. Zwelling, L. A., Michaels, S., Erickson, L. C., Ungerleider, R. S., Nichols, M., and Kohn, K. W. (1981). Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4′-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin. Biochemistry 20, 6553-6563.